Want to track MYNZ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
MYNZ Chart
Mainz Biomed B.V. Profile
| Diagnostics & Research Industry | Healthcare Sector | Mr. Guido Baechler CEO | NASDAQ (CM) Exchange | NL0015000LC2 ISIN |
| Germany Country | 65 Employees | - Last Dividend | 3 Dec 2024 Last Split | - IPO Date |
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
Contact Information
Address: Robert Koch Strasse 50
Phone: 49 6131 554 2860
Website: https://mainzbiomed.com
2024 © Marketlog. All Rights Reserved.
